Drugs / MVA/HIV62B
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01909414 | ? → Nov 2014 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MVA/HIV62B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01909414 ↗ |
| Modality | Vaccine | “a MVA HIV-1 (MVA/HIV62B) vaccine” NCT01909414 ↗ |
| Route | Intramuscular | “MVA/HIV62B vaccine will be administered as a 1 x 10\^8 TCID50 dose IM.” NCT01909414 ↗ |